Home / BUSINESS / FDC rises on entering into definitive agreement with GlaxoSmithKline Pharmaceuticals

FDC rises on entering into definitive agreement with GlaxoSmithKline Pharmaceuticals

FDC is currently trading at Rs. 161.75, up by 0.25 points or 0.15% from its previous closing of Rs. 161.50 on the BSE.

The scrip opened at Rs. 162.90 and has touched a high and low of Rs. 162.90 and Rs. 161.50 respectively.

The BSE group ‘A’ stock of face value Rs. 1 has touched a 52 week high of Rs. 219.95 on 31-Oct-2019 and a 52 week low of Rs. 148.20 on 19-Feb-2019.

Last one week high and low of the scrip stood at Rs. 163.35 and Rs. 152.50 respectively. The current market cap of the company is Rs. 2765.49 crore.

The promoters holding in the company stood at 69.07%, while Institutions and Non-Institutions held 14.62% and 16.31% respectively.

FDC has entered into definitive documents (including a trademark assignment deed) on October 16, 2019 with GlaxoSmithKline Pharmaceuticals (GSK) for acquiring the registered Trademark ‘ENTEROPLUS’ from GSK. The Company would have acquired all the rights of this Trademark/Brand ‘ENTEROPLUS’.

FDC is engaged in manufacture of specialized formulations, and oral rehydration salts (ORS).

Please share this news